PHIO PHARMACEUTICALS CORP (PHIO) Stock Price, Quote, News and Overview
NASDAQ:PHIO - Nasdaq - US71880W5013 - Common Stock - Currency: USD
PHIO Quote, Performance and Key Statistics
2.73
+0.03 (+1.11%)
The current stock price of PHIO is 2.73 USD. In the past month the price increased by 105.26%. In the past year, price decreased by -52.6%.
PHIO Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.09 | 306.02B | ||
| AMGN | AMGEN INC | 13.99 | 149.08B | ||
| GILD | GILEAD SCIENCES INC | 22.68 | 130.32B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1686.55 | 125.74B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.34 | 61.56B | ||
| ARGX | ARGENX SE - ADR | 318.82 | 36.23B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 30.51B | ||
| ONC | BEIGENE LTD-ADR | N/A | 24.88B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.74B | ||
| NTRA | NATERA INC | N/A | 20.02B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.15B | ||
| BIIB | BIOGEN INC | 7.2 | 17.36B |
Related stock screener links
About PHIO
Company Profile
Phio Pharmaceuticals Corp. is a biotechnology company, which engages in the development of immuno-oncology therapeutics. The company is headquartered in Marlborough, Massachusetts and currently employs 8 full-time employees. The company went IPO on 2012-05-10. The firm's INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The company is developing therapeutics that are designed to leverage INTASYL to target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. The firm's pipeline is focused on the treatment of cutaneous Squamous Cell Carcinoma (cSCC) and melanoma. Its product pipeline includes PH-762 and PH-894. PH-762 is an INTASYL compound designed to reduce the expression of cell death protein 1 (PD-1). PD-1 is a protein that inhibits T cells’ ability to kill cancer cells and is a clinically validated target in immunotherapy. PH-894 is an INTASYL compound that is designed to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, thereby affecting the immune system as well as the tumor.
Company Info
PHIO PHARMACEUTICALS CORP
11 Apex Drive, Suite 300A, Pmb 2006
Marlborough MASSACHUSETTS 01752 US
CEO: Gerrit Dispersyn
Employees: 8
Company Website: https://phiopharma.com/
Investor Relations: http://investors.phiopharma.com/investor-relations
Phone: 15087673861
PHIO PHARMACEUTICALS CORP / PHIO FAQ
What is the stock price of PHIO PHARMACEUTICALS CORP today?
The current stock price of PHIO is 2.73 USD. The price increased by 1.11% in the last trading session.
What is the ticker symbol for PHIO PHARMACEUTICALS CORP stock?
The exchange symbol of PHIO PHARMACEUTICALS CORP is PHIO and it is listed on the Nasdaq exchange.
On which exchange is PHIO stock listed?
PHIO stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for PHIO PHARMACEUTICALS CORP stock?
7 analysts have analysed PHIO and the average price target is 4.08 USD. This implies a price increase of 49.45% is expected in the next year compared to the current price of 2.73. Check the PHIO PHARMACEUTICALS CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is PHIO PHARMACEUTICALS CORP worth?
PHIO PHARMACEUTICALS CORP (PHIO) has a market capitalization of 13.05M USD. This makes PHIO a Nano Cap stock.
How many employees does PHIO PHARMACEUTICALS CORP have?
PHIO PHARMACEUTICALS CORP (PHIO) currently has 8 employees.
What are the support and resistance levels for PHIO PHARMACEUTICALS CORP (PHIO) stock?
PHIO PHARMACEUTICALS CORP (PHIO) has a resistance level at 2.74. Check the full technical report for a detailed analysis of PHIO support and resistance levels.
Should I buy PHIO PHARMACEUTICALS CORP (PHIO) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of PHIO, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of PHIO, evaluating the profitability, health, valuation and growth aspects
- PHIO PHARMACEUTICALS CORP (PHIO) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- PHIO PHARMACEUTICALS CORP (PHIO) Sales and EPS estimates to see what analysts future expectations are.
- PHIO PHARMACEUTICALS CORP (PHIO) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- PHIO PHARMACEUTICALS CORP (PHIO) Insider and Institutional Ownership to learn about the owners and their transactions.
- PHIO PHARMACEUTICALS CORP (PHIO) Stock Chart to make your own analysis
- PHIO PHARMACEUTICALS CORP (PHIO) Latest news and press-releases to stay up to date.
Does PHIO PHARMACEUTICALS CORP (PHIO) stock pay dividends?
PHIO does not pay a dividend.
When does PHIO PHARMACEUTICALS CORP (PHIO) report earnings?
PHIO PHARMACEUTICALS CORP (PHIO) will report earnings on 2025-05-07.
What is the Price/Earnings (PE) ratio of PHIO PHARMACEUTICALS CORP (PHIO)?
PHIO PHARMACEUTICALS CORP (PHIO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-6.48).
What is the Short Interest ratio of PHIO PHARMACEUTICALS CORP (PHIO) stock?
The outstanding short interest for PHIO PHARMACEUTICALS CORP (PHIO) is 1.4% of its float. Check the ownership tab for more information on the PHIO short interest.
PHIO Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to PHIO. When comparing the yearly performance of all stocks, PHIO is a bad performer in the overall market: 80.25% of all stocks are doing better.
PHIO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PHIO. PHIO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
PHIO Financial Highlights
Over the last trailing twelve months PHIO reported a non-GAAP Earnings per Share(EPS) of -6.48. The EPS increased by 47.32% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -124.61% | ||
| ROE | -151.39% | ||
| Debt/Equity | 0 |
PHIO Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to PHIO. The Buy consensus is the average rating of analysts ratings from 7 analysts.